Aflibercept treatment in patients with diabetic macular edema

Cover Page

Cite item

Full Text

Abstract

The article provides a brief description of diabetic macular edema pathogenesis highlighting the role of inflammation, along with a short review of aflibercept trials in diabetic macular edema patients. Three clinical cases of diabetic macular edema treatment with aflibercept (Eylea) intravitreal injections in treatment-naïve patients are described; therapy was performed for 1 year according to the scheme provided in the Summary of Product Characteristics.

About the authors

Yury S Astakhov

Academician I.P. Pavlov First St Petersburg State Medical University

Author for correspondence.
Email: astakhov73@mail.ru

MD, PhD, professor. Ophthalmology Department

Russian Federation, Saint Petersburg, Russia

Pavel A Nechiporenko

Academician I.P. Pavlov First St Petersburg State Medical University

Email: glaz@doctor.com

MD, PhD, assistant. Ophthalmology Department

Russian Federation, Saint Petersburg, Russia

References

  1. Adamis AP. Is diabetic retinopathy an inflammatory disease? Br J Ophthalmol. 2002;86:363-5. doi: 10.1136/bjo.86.4.363.
  2. Akirav EM, Baquero MT, Opare-Addo LW, et al. Glucose and in ammation control islet vascular density and beta-cell function in NOD mice: control of islet vasculature and vascular endothelial growth factor by glucose. Diabetes. 2011;60:876-83. doi: 10.2337/db10-0793.
  3. Alon T, Hemo I, Itin A, et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med. 1995;1:1024-8. doi: 10.1038/nm1095-1024.
  4. Bai Y, Ma JX, Guo J, et al. Müller cell-derived VEGF is a signi cant contributor to retinal neovascularization. J Pathol. 2009;219:446-54. doi: 10.1002/path.2611.
  5. Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol. 2009;54(1):1-32. doi: 10.1016/j.survophthal.2008.10.001.
  6. Bolz M, Schmidt-Erfurth U, Deak G, et al. Diabetic Retinopathy Research Group Vienna Optical coherence tomographic hyperreflective foci: a morphologic sign of lipid extravasation in diabetic macular edema. Ophthalmology. 2009;116:914-920. doi: 10.1016/j.ophtha.2008.12.039.
  7. Brown DM, Schmidt-Erfurth U, Do DV, et al. Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies. Ophthalmology. 2015;122:2044-52. doi: 10.1016/j.ophtha.2015.06.017.
  8. Canas-Barouch F, Miyamoto K, Allport JR, et al. Integrin-mediated neutrophil adhesion and retinal leukostasis in diabetes. Invest Ophthalmol Vis Sci. 2000;41:1153-8.
  9. Chen X, Zhou H, Gong Y, et al. Early spatiotemporal characterization of microglial activation in the retinas of rats with streptozotocin-induced diabetes. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2015;253(4):519-525. doi: 10.1007/s00417-014-2727-y.
  10. Ciombor KK, Berlin J. Aflibercept — A decoy VEGF receptor. Curr Oncol Rep. 2014;16:368. doi: 10.1007/s11912-013-0368-7.
  11. Coscas G, Coscas F, Vismara S, et al. Clinical features and natural history of AMD in Optical Coherence Tomography in Age-Related Macular Degeneration. Ed by G. Coscas, F. Coscas, S. Vismara, A. Zourdani, C. I. Li Calzi. Springer, Heidelberg, Germany; 2009. P. 171-194. doi: 10.1007/978-3-642-01467-3_9.
  12. Coscas G, De Benedetto U, Coscas F, et al., Hyperreflective dots: a new spectral-domain optical coherence tomography entity for follow-up and prognosis in exudative age-related macular degeneration. Ophthalmologica. 2012;229(1):32-37. doi: 10.1159/000342159.
  13. Do DV, Nguyen QD, Boyer D, et al. One-year outcomes of the DA VINCI Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology. 2012;119:1658-65. doi: 10.1016/j.ophtha.2012.02.010.
  14. Do DV, Schmidt-Erfurth U, Gonzalez VH, et al. The DA VINCI study: Phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema. Ophthalmology. 2011;118:1819-26. doi: 10.1016/j.ophtha.2011.02.018.
  15. Durukan AH, Memisoglu S, Gundogan FC. Is multifocal ERG a reliable index of macular function after triamcinolone acetonide injection in diffuse diabetic macular edema? Euro J Ophthalmol. 2009;19(6):1017-1027.
  16. Framme C, Schweizer P, Imesch M, et al. Behavior of SD-OCT-detected hyperreflective foci in the retina of anti-VEGF-treated patients with diabetic macular edema. Investigative Ophthalmology & Visual Science. 2012;53(9):5814-5818. doi: 10.1167/iovs.12-9950.
  17. Funatsu H, Noma H, Mimura T, et al. Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology. 2009;116:73-9. doi: 10.1016/j.ophtha.2008.09.037.
  18. Funatsu H, Yamashita H, Ikeda T, et al. Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology. 2003;110:1690-6. doi: 10.1016/S0161-6420(03)00568-2.
  19. Funatsu H, Yamashita H, Noma H, et al. Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. Am J Ophthalmol. 2002;133:70-7. doi: 10.1016/S0002-9394(01)01269-7.
  20. Funatsu H, Yamashita H, Sakata K, et al. Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema. Ophthalmology. 2005;112:806-16. doi: 10.1016/j.ophtha.2004.11.045.
  21. Gupta K, Kshirsagar S, Li W, et al. VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling. Exp Cell Res. 1999;247:495-504. doi: 10.1006/excr.1998.4359.
  22. Joussen AM, Murata T, Tsujikawa A, et al. Leukocyte-mediated endothelial cell injury and death in the diabetic retina. Am J Pathol. 2001;158:147-52. doi: 10.1016/S0002-9440(10)63952-1.
  23. Kang J-W, Chung H, Kim HC, Correlation of optical coherence tomographic hyperreflective foci with visual outcomes in different patterns of diabetic macular edema. Retina. 2016;36(9):1630-9. doi: 10.1097/IAE.0000000000000995.
  24. Kempen JH, O’Colmain BJ, Leske MC, et al. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol. 2004;122:552-63. doi: 10.1001/archopht.122.4.552.
  25. Klaassen I, Van Noorden CJ, Schlingemann RO. Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions. Prog Retin Eye Res. 2013;34:19-48. doi: 10.1016/j.preteyeres.2013.02.001.
  26. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin epidemiologic study of diabetic retinopathy. XV. The long-term incidence of macular edema. Ophthalmology. 1995;102:7-16. doi: 10.1016/S0161-6420(95)31052-4.
  27. Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology. 1984;91:1464-74. doi: 10.1016/S0161-6420(84)34102-1.
  28. Korobelnik JF, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121:2247-54. doi: 10.1016/j.ophtha.2014.05.006.
  29. Kowalczuk L, Touchard E, Omri S, et al. Placental growth factor contributes to micro-vascular abnormalization and blood-retinal barrier breakdown in diabetic retinopathy. PLoS One. 2011;6(3): e17462. doi: 10.1371/journal.pone.0017462.
  30. Leal EC, Manivannan A, Hosoya K, et al. Inducible nitric oxide synthase isoform is a key mediator of leukostasis and blood-retinal barrier breakdown in diabetic retinopathy. Invest Ophthalmol Vis Sci. 2007;48(11):5257-5265. doi: 10.1167/iovs.07-0112.
  31. Liu Q, Hu Y, Yu H, et al. Comparison of Intravitreal Triamcinolone Acetonide Versus Intravitreal Bevacizumab as the Primary Treatment of Clinically Signi cant Macular Edema. Retina. 2015;35(2):272-279. doi: 10.1097/IAE.0000000000000300.
  32. Lutty GA, Cao J, McLeod DS. Relationship of polymorphonuclear leukocytes to capillary dropout in the human diabetic choroid. Am J Pathol. 1997;151:707-14.
  33. Melder RJ, Koenig GC, Witwer BP, et al. During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat Med. 1996;2(9):992-997. doi: 10.1038/nm0996-992.
  34. Miyamoto K, Hiroshiba N, Tsujikawa A, Ogura Y. In vivo demonstration of increased leukocyte entrapment in retinal microcirculation of diabetic rats. Invest Ophthalmol Vis Sci. 1998;39:2190-4.
  35. Miyamoto N, de Kozak Y, Jeanny JC, et al. Placental growth factor-1 and epithelial haemato-retinal barrier breakdown: potential implication in the pathogenesis of diabetic retinopathy. Diabetologia. 2007;50(2):461-470. doi: 10.1007/s00125-006-0539-2.
  36. Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic population. Ophthalmology. 1998;105:998-1003. doi: 10.1016/S0161-6420(98)96025-0.
  37. Navarrete-Sanchis J, Zarco-Bosquets J, Tomas-Torrent JM, et al. Long-term effectiveness of vitrectomy in diabetic cystoid macular edema. Graefes Arch Clin Exp Ophthalmol. 2015;253(5):713-719. doi: 10.1007/s00417-014-2745-9.
  38. Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15:171-85. doi: 10.1007/s10456-011-9249-6.
  39. Park HY, Kim JH, Park CK. Neuronal cell death in the inner retina and the influence of vascular endothelial growth factor inhibition in a diabetic rat model. Am J Pathol. 2014;184(6):1752-1762. doi: 10.1016/j.ajpath.2014.02.016.
  40. Paulus YM, Gariano RF. Diabetic retinopathy: A growing concern in an aging population. Geriatrics. 2009;64(2):16-20.
  41. Prokofyeva E, Zrenner E. Epidemiology of major eye diseases leading to blindness in Europe: A literature review. Ophthalmic Res. 2012;47:171-88. doi: 10.1159/000329603.
  42. Rangasamy S, McGuire PG, Das A. Diabetic retinopathy and inflammation: novel therapeutic targets. Middle East Afr J Ophthalmol. 2012;19:52-9. doi: 10.4103/0974-9233.92116.
  43. Roy MS, Janal MN, Crosby J, Donnelly R. Inflammatory biomarkers and progression of diabetic retinopathy in African Americans with type 1 diabetes. Invest Ophthalmol Vis Sci. 2013;54:5471-80. doi: 10.1167/iovs.13-12212.
  44. Schoenberger SD, Kim SJ, Sheng J, et al. Increased prostaglandin E2 (PGE2) levels in proliferative diabetic retinopathy, and correlation with VEGF and inflammatory cytokines. Invest Ophthalmol Vis Sci. 2012;53:5906-11. doi: 10.1167/iovs.12-10410.
  45. Selim KM, Sahan D, Muhittin T, et al. Increased levels of vascular endothelial growth factor in the aqueous humor of patients with diabetic retinopathy. Indian J Ophthalmol. 2010;58:375-9. doi: 10.4103/0301-4738.67042.
  46. Shibuya M. Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis. BMB Rep. 2008;41(4):278-286. doi: 10.5483/BMBRep.2008.41.4.278.
  47. Stem MS, Gardner TW. Neurodegeneration in the pathogenesis of diabetic retinopathy: molecular mechanisms and therapeutic implications. Curr Med Chem. 2013;20:3241-50. doi: 10.2174/09298673113209990027.
  48. Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond). 2005;109(3):227-41. doi: 10.1042/CS20040370.
  49. Tsai CH, Chiang YC, Chen HT, et al. High glucose induces vascular endothelial growth factor production in human synovial fibroblasts through reactive oxygen species generation. Biochim Biophys Acta. 2013;1830:2649-58. doi: 10.1016/j.bbagen.2012.12.017.
  50. Uji A, Murakami T, Nishijima K, et al. Association between hyperreflective foci in the outer retina, status of photoreceptor layer, and visual acuity in diabetic macular edema. American Journal of Ophthalmology. 2012;153(4):710-717. doi: 10.1016/j.ajo.2011.08.041.
  51. Vinores SA, Youssri AI, Luna JD, et al. Upregulation of vascular endothelial growth factor in ischemic and non-ischemic human and experimental retinal disease. Histol Histopathol. 1997;12: 99-109.
  52. Vujosevic S, Berton M, Bini S, et al. Hyperreflective retinal spots and visual function after anti-vascular endothelial growth factor treatment in center-involving diabetic macular edema. Retina. 2016;36(7):1298-1308. doi: 10.1097/IAE.0000000000000912.
  53. Vujosevic S, Midena E. Retinal layers changes in human preclinical and early clinical diabetic retinopathy support early retinal neuronal and Muller cells alterations. Journal of Diabetes Research. 2013;2013. Article ID905058, 8 pages.
  54. Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. The New England Journal of Medicine. 2015;372:1193-1203. doi: 10.1056/NEJMoa1414264.
  55. White NH, Sun W, Cleary PA, et al. Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents. Diabetes. 2010;59(5):1244-1253. doi: 10.2337/db09-1216.
  56. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047-53. doi: 10.2337/diacare.27.5.1047.
  57. Yolcu U, Sobaci G. The effect of combined treatment of bevacizumab and triamcinolone for diabetic macular edema refractory to previous intravitreal mono-injections. Int Ophthalmol. 2015;35(1):73-79. doi: 10.1007/s10792-014-0019-5.
  58. Zeng H-Y, Green WR, Tso MO. Microglial activation in human diabetic retinopathy. Archives of Ophthalmology. 2008;(2):227-32. doi: 10.1001/archophthalmol.2007.65.
  59. Zhang X, Bao S, Lai D, et al. Intravitreal triamcinolone acetonide inhibits breakdown of the blood-retinal barrier through differential regulation of VEGF-A and its receptors in early diabetic rat retinas. Diabetes. 2008;57(4):1026-1033. doi: 10.2337/db07-0982.
  60. Zhang X, Zeng H, Bao S, et al. Diabetic macular edema: new concepts in patho-physiology and treatment. Cell Biosci. 2014;4:27. doi: 10.1186/2045-3701-4-27.
  61. Zhang Y, Ma J, Meng N, et al. Comparison of intravitreal triamcinolone acetonide with intravitreal bevacizumab for treatment of diabetic macular edema: A meta-analysis. Curr Eye Res. 2013;38(5):578-587. doi: 10.3109/02713683.2013.767351.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Astakhov Y.S., Nechiporenko P.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies